Navigation Links
Hutchinson Center scientists net $16.7 million for stem cell research
Date:10/8/2009

SEATTLE The National Heart, Lung and Blood Institute has awarded a total of $16.7 million to Irwin Bernstein, M.D., and Beverly Torok-Storb, Ph.D., both members of the Clinical Research Division at Fred Hutchinson Cancer Research Center. The Hutchinson Center grants represent part of a $170 million effort involving 18 teams of research scientists dedicated to developing stem- and progenitor-cell tools and therapies.

The seven-year awards create the NHLBI Progenitor Cell Biology Consortium, which assembles nine research hubs with multidisciplinary teams of principal investigators and an administrative coordinating center.

While a stem cell can renew itself indefinitely or differentiate, a progenitor cell can only divide a limited number of times and is often more constrained than a stem cell in the kinds of cells it can become. Given the potential of these cells for clinical applications, the consortium aims to identify and characterize progenitor cell lines, direct the differentiation of stem and progenitor cells to desired cell fates, and develop new clinical strategies to address the unique challenges presented by the transplantation of these cells.

Torok-Storb, along with Fred Hutchinson/University of Washington Cancer Consortium colleagues, will collaborate with Mortimer Poncz, M.D., of Children's Hospital of Philadelphia to develop molecular- and cell-based therapies for a range of blood diseases, with an initial focus on the delayed recovery of blood-clotting platelets following stem-cell transplantation, a life-threatening complication called thrombocytopenia.

The partner institutions will focus on two complementary strategies to address delayed platelet production. With their $8.2 million grant, Torok-Storb's team will develop reagents that can be administered to patients to stimulate the differentiation and proliferation of precursor cells into platelets. The Philadelphia group will work to generate "ex vivo," or outside the body, platelets and their precursors from embryonic stem cells for use as cell therapy.

Bernstein, along with Hutchinson Center/UW Cancer Consortium researchers and the University of Pennsylvania's Edward Morrisey, Ph.D., is using his $8.5 million award to determine how certain signaling pathwaysordered sequences of biochemical reactions inside cellsaffect cardiac and blood-forming cell development and cardiac regeneration and repair. The team will also study whether these pathways can be harnessed for therapeutic applications. Drawing on Bernstein's success in expanding cord-blood stem cells, the researchers hope to refine methods for deriving therapeutically useful numbers of cells for transplantation and other treatments.


'/>"/>

Contact: Kristen Woodward
kwoodwar@fhcrc.org
206-667-5095
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Federal stimulus funding channels more than $40 million to Fred Hutchinson Cancer Research Center
2. Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center
3. Hutchinson Metro Center Announces Over 50,000 SF in New Leases for Medical Space at Bronx Complex
4. Two Fred Hutchinson Cancer Research Center Scientists Receive Presidential Early Career Award
5. Kevin Hutchinson Appointed to Health IT Standards Committee
6. Gastroenterologists Applaud Kennedy-Hutchinson Bills Renewal of War on Cancer
7. Kevin Hutchinson Elected Vice Chair of Board of Directors for National eHealth Collaborative
8. Fred Hutchinson Cancer Research Center Benefits From Shopping Site
9. Fred Hutchinson Cancer Research Centers Inaugural Big Expedition for Cancer Research Begins in Alaska
10. Human-Research Protection Program at Fred Hutchinson Cancer Research Center Receives National Accreditation
11. Fred Hutchinson Cancer Research Centers Big Expedition for Cancer Research Team Returns From Reconnaissance Flight Over Alaskas Glacier Bay Park
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS ... Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. ... pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit for ...
(Date:4/24/2017)... CO (PRWEB) , ... April 24, 2017 , ... ... American Educational Research Association’s Outstanding Public Communication of Education Research Award. The award ... public, including education communities. It recognizes a scholar who has demonstrated the capacity ...
(Date:4/24/2017)... ... April 24, 2017 , ... Veteran Theresa James awoke ... changed her life forever. , In “Healing Tears,” James depicts every parent’s worst nightmare, ... my attorney, I began journaling conversations and situations throughout my divorce,” James said. “After ...
(Date:4/24/2017)... and Waycross, Ga. (PRWEB) , ... April 24, ... ... leader and trusted advisor within the telehealth industry, announces the company’s VideoMedicine mobile ... board-certified primary care providers. Available 24 hours a day, Quick Care provides patients ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant Management Solutions, was ... has been at the forefront of Gardant since it was founded in 1999. His ... the opening of more than 40 new senior living communities. With his leadership, Gardant ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... Viverae ® , a leader in workplace wellness technology, ... Watson Campaign Automation, implementing behavioral messaging within the ... experience. Through digital engagement, the platform prompts members to ... The enhanced experience drives engagement by focusing on the ... in their journey to health. Unlike ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
(Date:4/18/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded to ... will present preclinical data supporting the use of SPR741 ... Gram-negative infections at the 27th European Congress of Clinical ... Vienna, Austria . ... "Our ongoing preclinical research ...
Breaking Medicine Technology: